Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2011 June;59(3) > Minerva Cardioangiologica 2011 June;59(3):235-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  


Minerva Cardioangiologica 2011 June;59(3):235-8

language: English

Drug eluting stents for saphenous vein graft interventions

Banerjee S. 1,2, Master R. 2, Iqbal A. 2, Brilakis E. S. 1.2

1 VA North Texas Healthcare System, Washington, DC, USA
2 University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA


PDF  


Drug eluting stents (DES) have improved percutaneous coronary intervention (PCI) outcomes for most coronary lesion subsets and have gained widespread acceptance. This practice is supported by large-scale clinical trials. Evidence for DES use for treatment of saphenous vein graft (SVG) lesions is less well defined and often conflicting. Most SVG interventions are performed in the setting of an acute coronary syndrome (ACS), in large caliber vascular conduits with soft and friable plaque with inflammatory debris, without a fibrous cap. In this review, we provide an up to date assessment of the published evidence on DES use in PCI of SVG lesions.

top of page

Publication History

Cite this article as

Corresponding author e-mail

Subhash.banerjee@utsouthwestern.edu